Levi & Korsinsky, LLP announces that an SPRO class action lawsuit has been filed on behalf of investors who purchased Spero Therapeutics, Inc. (SPRO) securities between October 28, 2021, and May 2, 2022. For more on the SPRO Lawsuit please contact us today.

According to the Spero Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that:(i) the data submitted in support of the New Drug Application (“NDA”) for the Company’s product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration (“FDA”); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE SPRO CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Spero Therapeutics you have until July 25, 2022, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com